 acelRx Pharmaceuticals, Inc. (NASDAQ:ACRX ) reported fourth quarter 2019 net sales of $3.6 million which is 49% higher than the third quarter with solid growth expected for the rest of this year. 
 we also announced our previously previewed fourth quarter 2019 financial results and provided an update on our commercial launch of DSUVIA in a press release. these press releases and the slide presentation accompanying this call are available in the Investors section of our website at acelrx.com. earlier today, we announced the signing of a definitive agreement to acquire Tetraphase Pharmaceuticals, as well as entering into a co-promotion agreement which allows us to more quickly realize some key benefits from the transaction. 
 this is an important transaction that provides strategic benefits to both companies' shareholders. 
 we expect significant revenue and cost synergies as a result of the merger.    
 # 1_#1 _ # 1_#1 _ =    # 1 1.25 in.125 in.25 in 